The role of the Critical Event Committee in a major cardiovascular outcome study

被引:14
作者
Heagerty, A
Deverly, A
Palmer, C
Kaplinsky, E
Salvetti, A
Wahlgren, NG
Funck-Brentano, C
机构
[1] Univ Manchester, Dept Med, Manchester M13 9PL, Lancs, England
[2] Bayer Pharma Med Affairs, Paris, France
[3] Univ Cambridge, Ctr Appl Med Stat, Cambridge CB2 1TN, England
[4] Inst Heart, Tel Hashomer, Israel
[5] Univ Pisa, Pisa, Italy
[6] Karolinska Stroke Res, Stockholm, Sweden
[7] Hosp St Antoine, Paris, France
关键词
controlled trial; critical events; hypertension; INSIGHT Study; randomized;
D O I
10.1080/080370502321095294
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Outcome studies in cardiovascular diseases such as hypertension are often based in a number of countries recruiting from multiple centres. This can lead to difficulties in end-point evaluation and classification. The INSIGHT study provided the unique opportunity to examine the role and usefulness of a Critical Event Committee (CEC) established to examine all events occurring in a cohort of 6321 patients and classifying them according to pre-determined criteria. More than 28% of investigator-coded primary events and more than 41% of secondary events were re-classified by the CEC. Particularly difficult diagnoses included myocardial infarction, angina and heart failure, and the database finally analysed was substantially altered after CEC Committee evaluation. Post hoc analysis of the INSIGHT database demonstrated that the primary events compared would have been reduced from 6.3% vs 5.8% of those randomized on nifedipine vs co-amilozide to 5.1% vs 4.7% - an overall reduction of 72 events of 382, a fall of 18.8%. We conclude that a CEC should be a crucial component of any large outcome study and that if all events are subjected to scrutiny, the quality of the database is greatly enhanced.
引用
收藏
页码:339 / 344
页数:6
相关论文
共 10 条
[1]   Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) [J].
Brown, MJ ;
Palmer, CR ;
Castaigne, A ;
de Leeuw, PW ;
Mancia, G ;
Rosenthal, T ;
Ruilope, LM .
LANCET, 2000, 356 (9227) :366-372
[2]  
BROWN MJ, 1996, J HUMAN HYPERTENS S3, V10, P5157
[3]   The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension [J].
Estacio, RO ;
Jeffers, BW ;
Hiatt, WR ;
Biggerstaff, SL ;
Gifford, N ;
Schrier, RW .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (10) :645-652
[4]   Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:: the Captopril Prevention Project (CAPPP) randomised trial [J].
Hansson, L ;
Lindholm, LH ;
Niskanen, L ;
Lanke, J ;
Hedner, T ;
Niklason, A ;
Luomanmäki, K ;
Dahlöf, B ;
de Faire, U ;
Mörlin, C ;
Karlberg, BE ;
Wester, PO ;
Björck, JE .
LANCET, 1999, 353 (9153) :611-616
[5]   Randomised trial of old and new antihypertensive drugs in elderly patients:: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study [J].
Hansson, L ;
Lindholm, LH ;
Ekbom, T ;
Dahlöf, B ;
Lanke, J ;
Scherstén, B ;
Wester, PO ;
Hedner, T ;
de Faire, U .
LANCET, 1999, 354 (9192) :1751-1756
[6]   Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial [J].
Hansson, L ;
Zanchetti, A ;
Carruthers, SG ;
Dahlöf, B ;
Elmfeldt, D ;
Julius, S ;
Ménard, J ;
Rahn, KH ;
Wedel, H ;
Westerling, S .
LANCET, 1998, 351 (9118) :1755-1762
[7]   Disagreement between site investigators and clinical event committees is common and can affect trial results [J].
Mahaffey, KW ;
Tardiff, BE ;
Granger, CB ;
Lee, KL ;
Harrington, RA ;
Topol, EJ ;
Califf, RM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) :184A-185A
[8]   The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial -: Results with and without the end-point committee's final decision on end-points [J].
Näslund, U ;
Grip, L ;
Fischer-Hansen, J ;
Gundersen, T ;
Lehto, S ;
Wallentin, L .
EUROPEAN HEART JOURNAL, 1999, 20 (10) :771-777
[9]  
Thygesen K, 1999, EUR HEART J, V20, P708
[10]  
2000, INSIGHT WEBSITE